首页 / 院系成果 / 成果详情页

Efficacy and safety of P-CABs-based bismuth quadruple therapy for first-line Helicobacter pylori eradication: A real-world evidence study 期刊论文

编号：

4FA77167D455FC7287A28A772F7E2FA6
作者：

Ju, Kunping#^[1,2,3,4]Sun, Longfei^[1,2,3,4];Guo, Yuting^[5];Zhang, Lili^[6];Liu, Fengqing^[7];Zhai, Zhenzhen^[8];Zhao, Hongyu^[9];Li, Ruili^[10];Wang, Baobao^[1,2,3,4];Duan, Miao^[1,2,3,4];Kong, Qingzhou(孔庆周)*^[1,2,3,4]Li, Yueyue(李月月)*^[1,2,3,4]Zuo, Xiuli(左秀丽)^[1,2,3,4]Li, Yanqing(李延青)^[1,2,3,4]
语种：

英文
期刊：

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS ISSN：0924-8579 2026 年 67 卷 12 期 ; DEC
收录：
关键词：

Antibiotic combinations Helicobacter pylori Potassium-competitive acid blockers Quadruple therapy
摘要：

Objectives: This study aimed to evaluate the efficacy and safety of various bismuth-containing quadruple therapies with potassium-competitive acid blockers (P-CABs) for Helicobacter pylori eradication. Methods: This multicentre retrospective cohort study evaluated 1730 treatment-na & iuml;ve patients receiving P-CABs-based bismuth-containing quadruple therapies (P-BcQT). The regimens consisted of one PCAB (vonoprazan or tegoprazan), bismuth, and two antibiotics, including amoxicillin, clarithromycin, levofloxacin, tetracycline, and cefuroxime, with a treatment duration of 10-14 d. We comprehensively assessed eradication rates, adverse events, and risk factors predictive of positive results. Receiver operating characteristic curve analysis identified optimal cut-off values for predicting outcomes, while multivariate regression determined independent predictors of treatment failure and adverse events. Results: The overall eradication rate was 92.3% and 92.9% by modified intention-to-treat and per-protocol analysis, respectively. Multivariate analysis revealed three independent predictors of failure: high body surface area ( >= 1.76 m 2) (odds ratios: 1.545, 95% confidence intervals: 1.010-2.362, P = 0.045), low compliance (odds ratios: 3.442, 95% confidence intervals: 1.891-6.266, P < 0.001), and suboptimal antibiotic combinations. Especially, amoxicillin/clarithromycin ( P = 0.005) and cefuroxime/levofloxacin regimens ( P < 0.001) demonstrated significantly higher failure trend compared to amoxicillin/tetracycline combinations. The adverse event rate was 26.9%, with lower body mass index ( < 28.38 kg/m 2) ( P = 0.011) and long treatment duration ( P = 0.007) emerging as independent risk factors. Overall compliance was excellent (95.6%). Conclusions: P-BcQT demonstrated promising efficacy as a first-line H. pylori treatment regimen. However, regimens containing clarithromycin or levofloxacin appear less effective. Future optimisation may focus on shorter treatment durations, personalised dosing adjustments and regional resistance patterns. and International Society of Antimicrobial Chemotherapy. All rights are reserved,
推荐引用方式
GB/T 7714：

Ju Kunping,Sun Longfei,Guo Yuting, et al. Efficacy and safety of P-CABs-based bismuth quadruple therapy for first-line Helicobacter pylori eradication: A real-world evidence study [J].INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS,2026,67(12).
APA：

Ju Kunping,Sun Longfei,Guo Yuting,Zhang Lili,&Li Yanqing.(2026).Efficacy and safety of P-CABs-based bismuth quadruple therapy for first-line Helicobacter pylori eradication: A real-world evidence study .INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS,67(12).
MLA：

Ju Kunping, et al. "Efficacy and safety of P-CABs-based bismuth quadruple therapy for first-line Helicobacter pylori eradication: A real-world evidence study" .INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS 67,12(2026).
入库时间：

11/10/2026 3:24:47 PM
更新时间：

11/10/2026 3:24:47 PM

浏览次数：3  下载次数：0

分享到：

浏览次数：3

下载次数：0

打印次数：0